Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - framycetin sulfate 0.55%{relative} (at a framycetin potency of 670µg /mg);   - ear/eye drops - 0.55 % - active: framycetin sulfate 0.55%{relative} (at a framycetin potency of 670µg /mg)   excipient: benzalkonium chloride citric acid monohydrate sodium chloride sodium citrate dihydrate water for injection

Irska - engleski - HPRA (Health Products Regulatory Authority)

bgp products ltd - fenofibrate - capsules hard - 67 milligram - fibrates - serum lipid reducing agents/cholesterol and triglyceride reducers/fibrates - it is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: - treatment of severe hypertriglyceridaemia with or without low hdl cholesterol. - mixed hyperlipidaemia when a statin is contraindicated or not tolerated. - mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and hdl cholesterol are not adequately controlled.

Irska - engleski - HPRA (Health Products Regulatory Authority)

grünenthal ltd - fentanyl - tablet sublingual - 67 microgram - phenylpiperidine derivatives

Australija - engleski - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - caspofungin acetate, quantity: 55.5 mg (equivalent: caspofungin, qty 50 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; sucrose; hydrochloric acid - caspofungin kp is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: polysorbate 80; aluminium; histidine; sodium chloride; borax; water for injections - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: sodium chloride; histidine; borax; aluminium; water for injections; polysorbate 80 - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

Kanada - engleski - Health Canada

icu medical canada inc - dextrose; sodium chloride - solution - 33.3mg; 3mg - dextrose 33.3mg; sodium chloride 3mg - replacement preparations

Kanada - engleski - Health Canada

wood wyant canada inc - sodium dichloroisocyanurate - tablet - 55% - sodium dichloroisocyanurate 55% - disinfectants (for agents used on object)

Kanada - engleski - Health Canada

tyco healthcare - barium sulfate - paste - 55% - barium sulfate 55% - roentgenography

Kanada - engleski - Health Canada

nu skin international, inc. - triclosan - gel - .55% - triclosan .55% - miscellaneous local anti-infectives